header logo image


Page 562«..1020..561562563564..570580..»

Down woman’s arthritis tracker app for young adults aims to help and connect sufferers during coronavirus pandemic – Belfast Telegraph

May 7th, 2020 7:46 am

A Co Down woman is behind a mobile app to support teens and young adults living with arthritis during the coronavirus pandemic.

eading charity Versus Arthritis is launching the app today in the hope that it will help young people living with the debilitating condition, including the 15,000 children under the age of 16 who have juvenile idiopathic arthritis (JIA).

The arthritis tracker - which provides 24/7 access to trusted information and advice for young people between 13 and 25 - will help them to rate and record their arthritis symptoms in seconds and track their pain, medication side effects, fatigue, physical activity, sleep and emotional wellbeing.

Along with tracking their arthritis symptoms and wellbeing, the app also connects sufferers with other teenagers and young people who know what it is like to live with arthritis.

Hope Graham, from Warrenpoint, came up with the idea for the app as a result of her own painful experience of JIA.

She said: "Having an app that can help track symptoms is such a huge help.

"I have been in a lot of pain previously, but whenever I go to the doctor, I tend to say 'I'm okay, I'm not feeling that bad', but actually, I won't have been able to walk up the stairs a couple of weeks ago.

"I will be using the app all the time now. Being part of its development has already helped me to ensure I get the treatment I need when I visit my doctor. And being able to link up with other young people has completely changed the way I feel about my condition. I used to feel very alone.

"I hope that this app helps other young people to become part of a community, who are here to support each other."

An estimated 2.98m people under the age of 35 in the UK are living with a musculoskeletal condition like arthritis and the app will help young people enduring pain, fatigue and the isolation of arthritis, while also dealing with the everyday challenges of growing up.

Many people living with arthritis take immunosuppressant drugs and, as a result, they are amongst the 1.8m across the UK who currently have to shield themselves from Covid-19.

As a result, they have been unable to attend face-to-face hospital appointments and there are concerns this has made it more difficult to explain their symptoms. It is hoped the app, which is available from the Versus Arthritis website, will help to address this.

Belfast Telegraph

Read more:
Down woman's arthritis tracker app for young adults aims to help and connect sufferers during coronavirus pandemic - Belfast Telegraph

Read More...

COVID-19: Arthritis Drug Saves 72-year-old Critically Ill Patient with Grim Condition – Science Times

May 7th, 2020 7:46 am

On March 16, Leonard Whitehurst was admitted to the Royal Cornwall hospital with a confirmed case of COVID-19. His doctor, Giorgio Gentile, said that Whithurst's condition has deteriorated, describing it as "very grim."

Thankfully, the 72-year-old was saved after his doctors decided to give him a promising arthritis drug that is under clinical trials by doctors worldwide. Tocilizumab showed promising results in treating COVID-19 patients in Italy.

The drug is marketed as RoZctemra or Actemra, used to suppress the immune system of patients with rheumatoid arthritis. Its effect on COVID-19 has the potential to halt the cytokine storm that happens when the immune system goes into overdrive and begins attacking the body.

Mr. Whitehurst's condition instantly improved after he received the drug as a last-ditch attempt, and is now recovering at home. Dr. Gentile believes that Whitehurst us the first to try the arthritis drug in the UK back in March following the advice of doctors from other countries.

The tocilizumab drug is now part of the three major trials on British coronavirus patients, expecting its first results by June or July.

Dr. Gentile is a consultant nephrologist from Italy who has worked at the Royal Cornwall Hospitals Trust since 2015.

He said that Mr. Whitehurst was in critical condition, needing 19 liters of oxygen but had not been put on a ventilator. The 72-year-old patient was deteriorating quickly, and putting him into the intensive care unit was not an option as the patient was not prepared to be artificially ventilated, his outlook was very grim at that time.

Dr. Gentile was so desperate to save his patient that he gave him tocilizumab, which seemed the only option left to try and save his patient's life. He regularly reads medical literature of COVId-19 from different countries that are also battling the disease.

Furthermore, he became aware of the drug's multiple anecdotal reports of people having severe conditions that had dramatically improved because of the medication. He said that the AIFA- Italian equivalent of the Medicines and Healthcare products Regulatory Agency- had just approved a large scale test trial with tocilizumab and was actively recruiting people.

Another promising study of 20 patients from China claimed the efficacy of the drug, which cured 95% of critically ill patients.

Read Also: This Drug Is Voted As the Most Effective Coronavirus Cure Possible By 6,000 Doctors Worldwide

According to Dr. Gentile, Mr. Whitehurst had all the laboratory signs of the so-called "cytokine storm." With approval from the hospital and the patient, he decided to give him tocilizumab, which was administered quickly.

Mr. Whitehurst received two infusions of tocilizumab 12 hours apart, but before he was given the drug, his oxygen saturation was 75%, which is below the normal reading that should be between 80 and 100. His oxygen saturation improved very quickly after receiving the drug and kept improving gradually and steadily over the next days.

Mr. Whitehurst was discharged from the hospital last week, smiling and overjoyed, after spending more than a month in the hospital.

Tocilizumab is part of three major trials involving British patients. Results are expected by June or July, reported by MailOnline.

One of the big trials is the Recovery trial, which is testing four promising treatments such as HIV, malaria, and antibiotic drugs. They have already recruited about 6,000 NHS patients, which makes it the most extensive study looking at repurposing existing therapies to treat COVId-19. The drug will be administered to patients whose lungs have been severely damaged due to the virus.

Meanwhile, Chinese doctors were the first to try tocilizumab on patients given routine therapies who were diagnosed as severe or critical. After a few days, the patients' fever returned to normal and improved dramatically, according to Dr. Xiaoling Xu and his colleagues.

CT also showed damage to the lungs reduced significantly around the fourth and fifth day of treatment. The authors concluded that tocilizumab is an effective treatment among patients with severe cases of COVID-19.

Read More: Italian Scientists Claim the World's First COVID-19 Vaccine That Can Neutralize Coronavirus in Human Cells

Read this article:
COVID-19: Arthritis Drug Saves 72-year-old Critically Ill Patient with Grim Condition - Science Times

Read More...

Coronavirus: New app developed to help young arthritis sufferers through pandemic – The Courier

May 7th, 2020 7:46 am

A Dundee University student is among those being helped by a new mobile app aimed at helping teenagers and young adults with arthritis through Covid-19 self-isolation.

Melissa Tavendale said she had already felt the benefit of the Arthritis Tracker which provides round-the-clock access to information and advice, helping those affected to rate and record symptoms in seconds and track their pain, medication side effects, fatigue, physical activity, sleep and emotional well-being.

An estimated 2.98 million people under the age of 35 in the UK are living with a musculoskeletal (MSK) condition and the charity Versus Arthritis has launched the app.

Versus Arthritis digital engagement officer, Sophie Mullen said; Arthritis is too often dismissed as an old persons disease, but it doesnt discriminate by age two thirds of people with arthritis are under 65.

Technology is helping us bridge the gap to those who were already isolated, and who face more restrictions to their life because of Covid-19.

Most will never have met other young people their age with the condition, who understand what theyre going through. This app will help us change that.

Melissa, 19, was recently diagnosed with Seronegative inflammatory arthritis after experiencing painful joints and stiffness for more than a year.

Now living with her parents in the north east during lockdown, she has already had one medical appointment cancelled during the pandemic.

The app is very easy to use and seems to be working very well. I like the extra info with tips and advice about managing my condition, she said.

View original post here:
Coronavirus: New app developed to help young arthritis sufferers through pandemic - The Courier

Read More...

Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis…

May 7th, 2020 7:46 am

AIMS:

Adalimumab-adbm is a monoclonal antibody developed as a biosimilar to adalimumab (Humira, AbbVie Inc.). The key objectives of this study were using a population pharmacokinetic (PPK) approach to assess pharmacokinetic (PK) similarity between adalimumab-adbm and Humira in patients with activerheumatoid arthritis(RA), to quantify the effects of potential covariates on adalimumab PK, and to assess the impact of switching treatment from Humira to adalimumab-adbm on PK.

A PPK model was firstly developed using intensive PK data from the phase 1 study in healthy subjects (NCT02045979). PPK models were developed separately for phase 3 base study (NCT02137226) and its extension study (NCT02640612) in patients with active RA.

PPK models were developed for adalimumab from adalimumab-adbm and Humira treatment in healthy subjects and RA patients. Weight and anti-drug antibodies (ADA) were found to be important predictors of adalimumab clearance. Adalimumab PK was similar between adalimumab-adbm and Humira. The estimated effect of Humira on clearance, relative to the adalimumab-adbm, was 1.02 (i.e., Humira has 0.02 greater clearance). Similarly, the effect of treatment arms (switching) on clearance was estimated to be 1.00 and 0.997 for Humira:Humira:BI and Humira:BI:BI arms, respectively, relative to the BI:BI:BI arm (BI refers to adalimumab-adbm) in the phase 3 extension study.

PK similarity between adalimumab-adbm and Humira in patients with active RA was demonstrated using PPK approach. Adalimumab PK was also similar when switching treatment from Humira to adalimumab-adbm at either week 24 or 48.

See the original post here:
Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis...

Read More...

How One Woman Found Freedom From RA – HealthCentral.com

May 7th, 2020 7:46 am

In a sun-dappled dance studio with floor-to-ceiling windows in Summit, NJ, Teresa D'Angelo is leading a class full of female students through a series of graceful, flowing moves. They raise their arms to the sky and sway side to side, their heads tossed back with abandon. They bow down towards their bare feet, sweeping their hands along the floor as if gathering leaves from a garden, then transition into a series of sensual shoulder rolls.

Now, the pace changes. DAngelo, who rocks a blonde pixie cut and has a radiant, infectious smile, begins performing a series of sidekicks, upward blocks, and other martial arts-inspired moves. The women follow along, full of fierce determination, but the grins never once leaving their faces. After 60 minutes, they end class in a warm group embrace, beaming and trading words of support and encouragement.

After everyone had gone home, DAngelo spends a bit more time in the studio, this time dancing solo. In her hands is a pumpkin-colored silk scarf, which she traces through the air as she completes a series of balletic twirls, dipping down low then rising up on her tiptoes. With the sun streaming in and the scarf billowing in the air, she looks like a triumphant butterfly.

You would never know that several years prior, DAngelo spent her days lying on a couch in her living room, racked by excruciating joint pain and inflammation from rheumatoid arthritis (RA). She needed a cane to make it to another room and moved up and down the stairs by scooting on her bottom. Turning a doorknob was impossible.One day, she caught sight of herself hunched over in a mirror and thought, Oh my God, is this what the rest of my life is going to be like?

The answer, she ultimately decided: Hell, no. This is the story of her transformation, made possible by a chance encounter with a doctor and a decision DAngelo, now 58, made to listen to her body and start moving the way it wanted to.

In 2005, DAngelo was working for an international accounting and consulting firm in a job that paid well but required sitting at a desk for up to 10 hours a day and left her feeling boxed in and spiritually stifled. None of this was a great fit for the former ballet dancer who, as a young girl in the 70s, had aspired to become a prima ballerina. Her hopes were extinguished at the age of 15 by an instructor named Miss J, who always wore black leotards, black rock-star eyeliner, and raised her voice a lot. If she yelled at you, it meant she took interest, DAngelo recalls. I don't remember being yelled at a lot.

After that, she threw her energy into high school and college, where she discovered a new love, communications. She was a radio DJ in undergrad, a weekend weather anchor while earning her masters degree, and later, a managing editor. Im not shy, but Ive always been on the quieter side, so I loved how these jobs gave me the chance to speak out and communicate with many people at once, she says.

In May of 2005 DAngelo began experiencing some brain fog. I was having trouble absorbing information and struggling to react quickly at work, which was impacting my job because it was a stressful, high-performing environment, DAngelo recalls now. After a few months of mental fuzziness, another bizarre symptom hit. One day I noticed some swelling and pain in my left foot, she says. It came out of nowhere.

She told her naturopathic doctor, who directed her to a primary-care doctor, who in turn suggested she see a rheumatologist. That specialist diagnosed DAngelo with psoriatic arthritis (PsA), an autoimmune disease characterized by joint pain and stiffness plus psoriasis, a skin condition that causes red lesions that can burn, sting, or itch. (DAngelo didnt have lesions, but says her doctor based the diagnosis on bloodwork and her description of her pain. Some patients with PsA dont have the skin component.)

The doctor prescribed a biologic medication, a type of potent anti-inflammatory. DAngelo, who had for decades relied on herbal tinctures, green juices, probiotic-rich foods and other alternative therapies to maintain her health, initially balked at the suggestion. But when even her naturopathic doctor said he didnt think he could help her, DAngelo filled the prescription and, to her surprise and delight, began to feel better. The relief, she says, made her a bit cocky and she stopped taking the drug without asking her physician. It turned out to be the wrong move.

By the fall of 2005, pain and swelling began to hit her wrists and knees. The fact that her new symptoms were double-sided did not go unnoticed by her doctors. They said rheumatoid arthritis usually affects the joints symmetrically, but psoriatic arthritic tends to be just one-sided. That, along with further bloodwork, prompted DAngelos rheumatologist to change her diagnosis to RA and prescribe prednisone.

The powerful steroid worked intermittentlyDAngelo, at this point 43 years old, would have good days, going to work and the gym and playing catch outside with her son, Michaeland bad days, where her knees would swell with fluid, forcing her to use a cane.

At a routine appointment with her naturopath (I was still throwing everything I could at my RA in addition to my medication, she says), DAngelos doctor, noticing her increasing stiffness, said: You need to start moving your body. What do you like to do? She mentioned that she used to be a dancer. That prompted him to mention a movement-based mind-body practice called Nia.

Blending movements and philosophies from the worlds of dance, martial arts, and mindfulness, Nia is a non-impact workout thats performed barefoot, set to a diverse array of music (Latin, Jazz, Indian, and hip-hop, to name a few), and based on the premise that health can be discoveredor re-discoveredthrough conscious, meditative movement.

Exhilarated by the notion, DAngelo took a Nia class and instantly fell in love with it. It was like nothing Id ever done before. In ballet, I was always told exactly how to move. In Nia, youre given permission to move exactly how your body tells you.

During that first class, DAngelo noticed her body soften. The pain and stiffness were still there, but I felt peaceful and connected to myself. A sense of joy and relief flooded her body. I thought, Oh my gosh, Im moving again.

With more classes came more self-discovery and introspectionand some RA symptom relief. Like so many people, I started life as a vibrant soul with fantastic dreams and a creative imagination. But over time, the real me, the passionate and lively me, started to become quiet. My voice shut down and my body soon followed.

Now, dabbling in Nias 52 classic moveswhich at times resemble belly dancing, tai chi, ballet, and even salsa dancingthe old DAngelo was back. Through these shapes and movements, I could say and show what was going on inside of me. I was expressing through my body what had been bottled inside for many yearsmy voice.

Her love of dance rekindled, DAngelo signed up to become a Nia instructor herself. She made it halfway through her weeklong training in November of 2005, only to be sidelined by pain. I was on the floor of the studio, crying because it hurt to move, and a trainer, who I loved, said, Its OK, dont push yourself. Rest. It will be OK. Devastated, she reluctantly pulled out of training.

In early 2006, after a few months of rest combined with home Nia practice (I would pull myself together and practice one routine a night), DAngelo became officially certified as a Nia White Belt Instructor. (Like martial arts, Nia certification levels involve different colored belts). She soon began teaching a regular Saturday class at a local wellness center. Her dance dreams were finally coming to fruition.

One night shortly thereafter, DAngelo woke up screaming in pain. It felt like razor blades were cutting my wrists from the inside, she says. As her new husband Mike (they had married in August) tried to comfort her, she prayed out loud, begging for relief.

This cycle was the first of many highs and lows that were to come over the next two years, as DAngelo continued working for her firm and teaching Nia on Saturdays. On one hand, she had the satisfaction of knowing she was helping other womensome living with chronic illnessfind a release from stress, and often pain (many Nia practitioners discover the class during a chronic-pain journey). On the other hand, she would spend weeks off and on steroids and never knew when the inflammation would hit. I could have a great class one day, tons of energy, no pain, then wake up the next morning and have trouble getting out of bed.

Things took a turn for the worse between 2008 and 2011. Her wrists and occasionally ankles hurt. Her knee needed to be drained with a needle every few weeks to release fluid build-up. A headache so bad she feared it was a brain tumor sent her to the emergency room. When travelling on firm business, shed leave team dinners early to go to bed and strategically wore a neoprene arm brace so colleagues and new associates wouldnt shake her hand, as doing so would leave me screeching in pain. She took three leaves of absence from work between 2005-2011.

In 2011, after several months of being couch-bound and unable to teach Nia, let alone work, DAngelo had a doctors appointment. She was surprised to learn her rheumatologist was out and shed be seeing a different specialist that day. That fresh set of eyes turned out to be a blessing for DAngelo. She said, Lets take you off these high doses of prednisone and try to find another medication that actually will help you.

The next few months were spent experimenting with multiple RA drugs. No luck. Then, in January of 2012, the doctor wanted to try yet another. The whole process had been intimidating. But so was the thought of not being able to sway and twirl and be in her body the way Nia allowed her to be.

At home that day, lying on the couch, I remember asking God, What do you want me to do? she recalls. And like a waterfall of calm, I felt the words, Take the medicine wash over me.

Around the same time, a friend who is an integrative psychotherapist visited Teresa at home. She asked me, What is your vision of yourself? I said, I see myself as a ballet dancer, leaping over the moon. DAngelos friend replied, Hold that vision.

Together, those two key events convinced her to try the new treatment.Slowly, she began feeling less fatigued. Her joint inflammation lessened. Her pain reduced. By March, about two months after starting, she started to feel like herself again and was cleared by her rheumatologist to return to work.

Just a few days later, she received a call from human resources; she was being laid off. DAngelos response?

I put the phone on mute, pumped my fist, and said YES! That job had been so stressful for so many years. I thought maybe now I could start helping people who were like me and show them how to use movement to regain their life and wellness. Maybe, she thought, she could even turn it into a business.

In 2014, she launched Live Love Move, a company based in her hometown of Summit, NJ that offers mindful movement classes, workshops, and retreats for women, particularly those living with chronic pain. Now a first-degree black-belt instructor and certified massage instructor whos also working on her certification in dance movement therapy, DAngelo works with students who range from teachers and nurses to CEOs and stay-at-home moms. When they start to move, they sometimes cry simply because the act of lifting your hands to the sky can feel so empowering and releasing, she describes. The trauma of their illness has been locked inside. Now, they feel heard and seen.

DAngelo, is still taking the same medicine and is more or less pain-free. She does have osteoporosis in her right hip, which her doctor believes is a result of years of steroid use, and occasional morning stiffness, which she describes as crankiness in my knees and wrists.

Nutrition plays a big role in her life; she follows an anti-inflammatory diet, avoids gluten and tries to limit sugar to what she gets from fruit. My doctor tells me: Whatever youre doing, keep doing it.

Equally important has been recasting her RA diagnosis as a gift, something she says took her nearly a decade to do. Ultimately, though, the pain of not being able to move, of believing my body betrayed me, it helped me to seek and find the gift of my voice through dance. I not only feel better physically, but I handle stress better. Now, its my mission to educate and inspire othersanybody who hasnt moved in a long time or wants to move differently.

When meeting with a new group, she usually kicks things off with these words: Hi, Im Teresa DAngelo. I help support people who are in pain to help them feel better through healing movement. Even if you can just move a finger, ankle, or toe, know that pain is not the end of your story.

View post:
How One Woman Found Freedom From RA - HealthCentral.com

Read More...

Cover Corona Outbreak: Rheumatoid Arthritis Diagnosis Tests Market 2020 Industry Growth Analysis, Segmentation, Size, Share, Trend, Future Demand And…

May 7th, 2020 7:46 am

The Latest Research Report on Rheumatoid Arthritis Diagnosis Tests Market size | Industry Segment by Applications, by Type, Regional Outlook, Market Demand, Latest Trends, Rheumatoid Arthritis Diagnosis Tests Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025. Analyzes current market size and upcoming 5 years growth of this industry.

According to the report, the Rheumatoid Arthritis Diagnosis Tests market is projected to register high demand during the forecast period with increasing demand from major end-use industries such as increasing demand due to growing inclination towards the use of renewable energy during the forecast period.

Click here to get sample of the premium report: https://brandessenceresearch.com/requestSample/PostId/316

A combined cycle power plant is a heat engine assembly that works in conjunction from the same heat source, converting it into mechanical energy that generally drives electrical generators in turn. The concept is that the operating fluid temperature in the system is still high enough after completing its cycle that a second subsequent heat engine extracts energy from the heat generated by the first engine.

With an emphasis on both organic and inorganic growth strategies, there have been several primary developments done by major companies include

Antibodies Inc., Euro Diagnostica AB, Qiagen NV, Siemens Healthcare GmbH, Bio Rad Laboratories Inc., Genway Biotech, Inc., Abbott Diagnostics, Beckman Coulter, Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc. and others.

Key Factors Impacting Market Growth:

o Increasing demand due to growing inclination towards the use of renewable energy.

o Strict government regulations directing various industries towards reducing their carbon footprint

o New developments in the clean energy sector, prompting companies to expand the horizon for CCGT market globally

Market Segmentation:

By Type:Serology TestsErythrocyte Sedimentation rateAnti-Cyclic Citrullinated PeptideRheumatoid FactorAntinuclear AntibodyUric AcidOthersMonitoring Rheumatoid Arthritis Treatment Efficiency TestsMuscle Enzyme TestsSalicylate Level CountCreatinine TestBy End-User:HospitalsDiagnostics LaboratoriesAmbulatory Surgical Centers

Request Customization of the premium report: https://brandessenceresearch.com/requestMethodology/PostId/316

Customization:

We provide customization of the study to meet specific requirements:

o By Segment

o By Sub-segment

o By Region/Country

Regional segmentation and analysis to understand growth patterns:

The market has been segmented in major regions to understand the global development and demand patterns of this market.

Detailed information for markets like North America, Western Europe, Eastern Europe, Asia Pacific, Middle East, and Rest of the World is provided by the global outlook for the Rheumatoid Arthritis Diagnosis Tests market. During the forecast period, North America and Western Europe are projected as main regions for the shortwave infrared sector. As one of the developed regions, the energy & power sector is important for the operations of different industries in this area.

This is one of the key factors regulating Rheumatoid Arthritis Diagnosis Tests market growth in those regions. Some of the major countries covered in this region include the USA, Germany, United Kingdom, France, Italy, Canada, etc.

During the forecast period, the Asia Pacific is expected to be one of the fastest-growing regions for the Rheumatoid Arthritis Diagnosis Tests market. Some of the fastest-growing economies and increasing energy & power demand to cater for high population & industries are expected to drive demand in this area. During the forecast period, China and India are expected to record large demand. During the forecast period, the Middle East which includes the UAE, Saudi Arabia, Iran, Qatar, and others promises high market potential. In terms of market demand during the forecast period, the rest of the world including South America and Africa are developing regions.

This report provides:

1) An overview of the global market for Rheumatoid Arthritis Diagnosis Tests market and related technologies.

2) Analysis of global market trends, yearly estimates and annual growth rate projections for compounds (CAGRs).

3) Identification of new market opportunities and targeted consumer marketing strategies for global Rheumatoid Arthritis Diagnosis Tests market.

4) Analysis of R&D and demand for new technologies and new applications

5) Extensive company profiles of key players in the industry.

The researchers have studied the market in-depth and have developed important segments such as product type, application, and region. Each and every segment and its sub-segments are analyzed based on their market share, growth prospects, and CAGR. Each market segment offers in-depth, both qualitative and quantitative information on market outlook.

Full Access to the Report: https://brandessenceresearch.com/requestSample/PostId/316

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Contact Us:

https://brandessenceresearch.biz/

Brandessence Market Research & Consulting Pvt ltd.,

Kemp House, 152 160 City Road, London EC1V 2NX

+44-2038074155

[emailprotected]

View post:
Cover Corona Outbreak: Rheumatoid Arthritis Diagnosis Tests Market 2020 Industry Growth Analysis, Segmentation, Size, Share, Trend, Future Demand And...

Read More...

Ixekizumab Superior to Secukinumab in Providing More Quality-Adjusted Life-Years in Psoriatic Arthritis – Rheumatology Advisor

May 7th, 2020 7:46 am

Compared with secukinumab, ixekizumab provides more quality-adjusted life-years (QALYs) to patients with psoriatic arthritis (PsA) and concomitant moderate to severe plaque psoriasis at a marginally lower cost, according to study results published in PharmacoEconomics Open.

In this study, investigators in the United Kingdom conducted cost-effectiveness analyses comparing ixekizumab and secukinumab, 2 interleukin-17A antagonist biologic disease-modifying antirheumatic drugs (bDMARDs) with similar treatment efficacy of PsA. Researchers sought to determine the treatment arm that achieved maximal clinical improvement while minimizing health costs to both patients and the healthcare system.

Using a Markov model, which is based on the York model, the investigators included a hypothetical cohort of adult patients with PsA and concomitant moderate to severe plaque psoriasis and simulated 4 health states, including a bDMARD trial period, continuous therapy, best supportive care, and death, along with 4 treatment options that aligned with UKs National Health Service (NHS) practice guidelines. The population and characteristics of patients were modeled from data derived from previous intent-to-treat trial populations. Data for each treatment arm were extrapolated from a network of meta-analysis for both therapeutics. Researchers used 2 clinical scoring criteria, including PsA Response Criteria and Psoriasis Area and Severity Index (PASI), to determine response to treatment. Quality of life was assessed using a health assessment questionnaire, and resource cost included treatment cost, physician visit, and medication administration costs, and an algorithm estimating the cost of care depending on the PASI and health assessment questionnaire scores.

Results indicated that ixekizumab vs secukinumab demonstrated slightly lower total costs of care and higher total QALYs in both bDMARD-naive and -experienced patients (155,455 vs 155,530 and 8.127 vs 7.989, and 140,051 vs 140,264 and 3.996 vs 3.875, respectively). Consistent results were derived from the various sensitivity analyses carried out in this model, which the researchers noted can be adapted to countries with reimbursement and treatment practices different to those in the UK.

Study limitations included lack of data availability since rheumatoid arthritis data were used for health resource cost estimates instead of PsA data, the use of therapeutic list pricing instead of the confidential preferred price used by the NHS, and the exclusion of data on patient preferences of treatment options.

Researchers concluded, Although total costs and QALYs were quite similar for ixekizumab and secukinumab, with a modest advantage to ixekizumab for both parameters in bDMARD-naive and -experienced patients with PsA and concomitant moderate to severe psoriasis, we believe the findings of our analysis still provide insights that may be helpful for healthcare decision-makers when allocating resources.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Schweikert B, Malmberg C, kerborg , et al. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab in the treatment of active psoriatic arthritis with concomitant moderate to severe psoriasis in the UK [published online on March 12, 2020]. Pharmacoecon Open. doi:10.1007/s41669-020-00202-1

Continue reading here:
Ixekizumab Superior to Secukinumab in Providing More Quality-Adjusted Life-Years in Psoriatic Arthritis - Rheumatology Advisor

Read More...

Cracking the Lyme disease code – WSU News

May 7th, 2020 7:46 am

Abdul Lone

By Josh Babcock, College of Veterinary Medicine

The next time a tick feeds on you, Washington State University researchers hope to make sure persistent arthritis caused by Lyme disease doesnt linger for a lifetime.

Troy Bankhead, associate professor in WSUs Veterinary Microbiology and Pathology department, and his team have spent more than a decade analyzing an immune evasive protein of Borrelia burgdorferi, the bacterium that causes tick-borne Lyme disease.

With the labs latest finding, that work is beginning to pay off.

According to research recently published in Cell Reports, Bankhead and assistant research professor Abdul Lone discovered that a surface protein known as VlsE acts as a shield to prevent the immune system from effectively fighting the disease. In particular, the study examined how VlsE protects one of the main proteins responsible for Lyme diseases persistent arthritis.

This really has a significant impact in the development of vaccines, Bankhead said.If we can determine which proteins are shielded as opposed to which ones are not, then of course those that are not protected are going to be better candidates for a vaccine.

The Centers for Disease Control and Prevention estimates some 300,000 people may get Lyme disease each year in the United States alone. It is most prevalent in the northeast.

If not treated early with antibiotics, Lyme disease can cause lifelong arthritis, and in more severe cases, bladder infections, heart inflammation, and neurologic and cognitive issues like loss of memory and balance.

We chose the arthritis-related protein because arthritis is the most common symptom you see in North America, Lone said.

By engineering a strain of Borrelia burgdorferi in the lab without the surface lipoprotein VlsE, they were able to confirm it was protecting the arthritis-related protein from an antibody response.

Bankhead and Lone tested the new Borrelia strain in mice and found the animals were more easily able to clear the infection.

Then, Bankhead and Lone confirmed that the new Borrelia strain was susceptible to antibodies under the microscope.

By using fluorescence microscopy, a process that uses energy from electrons to emit light under a microscope, Bankhead and Lone watched as antibodies were unable to bind to the protein responsible for Lymes persistent arthritis when the VlsE protein was present. When the VlsE protein was removed, antibodies were able to recognize and bind to the arthritis-related protein.

When you dont have VlsE those bacteria light up and that is because those antibodies are able to bind and recognize that arthritis-related protein in the absence of that VlsE shield, Bankhead said. Thats exactly what we were seeing.

Understanding the VlsE protein is acting as a shield for the bacteriums arthritic-causing protein is significant for vaccine development and future research. While it is unknown if other surface proteins are protected, Bankhead said it is likely. He noted the scientific community is gaining ground on understanding these proteins but producing any vaccine is well into the future.

Still, the finding creates two avenues for researchers to eliminate Lyme disease: take down the VlsE shield, or, find a way for the antibody response to get in front of the ever-adapting bacterium and eliminate it.

HIV/AIDS persists for years in human beings. The same thing happens with Borrelia, it persists, Lone said. While this finding tells us a lot about Borrelia. Our next step is to understand how it persists. Once we understand the mechanism of persistence, we can eliminate the disease.

Read the original:
Cracking the Lyme disease code - WSU News

Read More...

Global Arthritis Therapeutic Market: Industry Analysis and forecast (2019 to 2026): By Type, Drug Class, Route of Administration, Distribution Channel…

May 7th, 2020 7:46 am

Global Arthritis Therapeutics Market was valued USD XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of 4.8 % during forecast period of 2019 to 2026.

The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.Arthritis is an inflammatory disorder affecting the joints cause redness, stiffness, resulting in pain and swelling in the joints. More than 100 categories of arthritis are affecting the global population. The most common arthritis conditions are psoriatic arthritis, rheumatoid arthritis, and osteoarthritis. The osteoarthritis affects a majority of the geriatric population, in severe joint pain and affecting their movement. Psoriatic Arthritis therapeutics contains drugs that help to reduce pain and inflammation.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/36112

Global Arthritis Therapeutic Market Drivers and RestrainsThe significant growth of the global arthritis therapeutics market is credited to investments in research & development, strong product pipeline, increasing patient pool suffering from arthritis. Furthermore, rise in the geriatric population is another factor fueling the growth of the global arthritis therapeutics market. Patients gone under treatment with Disease-Modifying Antirheumatic Drugs (DMARDs) are unsatisfied because of poor therapeutic benefits. The dominance of rheumatoid arthritis globally, the launch of novel therapeutic agents, and favorable reimbursement policies for high-cost treatment products are the factors that boost the growth of global arthritis therapeutics market. In 2016, the International Federation of Psoriasis Association (IFPA) states that more than 125 Mn people were affected with psoriasis. It is estimated that between 11% and 32% of patients with psoriasis incline to develop psoriatic arthritis. Furthermore, nearly 52.2 million adults suffered from arthritis in U.S. alone in 2015. Developments in diagnostics and healthcare infrastructure in developing countries are projected to witness an increased number of diagnosed patients.

Manufacturers in the Arthritis Therapeutic are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

Global Arthritis Therapeutic Market Segmentation AnalysisBy Arthritis Therapeutic Market is segmented into Psoriatic Arthritis, Rheumatoid Arthritis, Osteoarthritis, Gout and Others. Rheumatoid Arthritis and Psoriatic Arthritis segment is expected to exhibit highest global market share at a CAGR of xx% over forecast period. Increasing occurrence of arthritis diseases globally, is likely to drive key players to develop novel therapeutics treatment for the disease. Strong research and development by key companies supported by huge investments is projected to drive the global arthritis therapeutics market. In 2018, according to the WHO statistics 9.9 % of men AND 18.1 % of women over the age of 60 suffered from osteoarthritis, symptomatic, worldwide. About 80 % of those with osteoarthritis have limitations in movement, and 25 % of women over the age of 60 suffered from symptomatic osteoarthritis, globally.

Global Arthritis Therapeutic Market Regional AnalysisThe Global Arthritis Therapeutic Market has been classified into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East Africa. North America dominated the global arthritis therapeutics market, followed by Europe. Because of a large patient pool suffering from arthritis diseases, like osteoarthritis, rheumatoid arthritis and other conditions. Advantageous reimbursement policies, launching of novel biologics drugs, well-defined regulatory framework, and availability of biosimilars are boost up the market growth in the region. Furthermore, the presence of key players in the region and a strong product pipeline for arthritis treatment are projected to drive the arthritis therapeutics market in the region. This can be ascribed to awareness about arthritis, presence of key players, growing patient pool, favorable reimbursement policies, and availability of biosimilar and biologics arthritis drugs in the region.

The objective of the report is to present comprehensive analysis of Global Arthritis Therapeutic Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Arthritis Therapeutic Market dynamics, structure by analyzing the market segments, and project the Global Arthritis Therapeutic Market size. Clear representation of competitive analysis of key players by Arthritis Therapeutic Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Arthritis Therapeutic Market make the report investors guide.

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/36112

Scope of the Global Arthritis Therapeutic Market

Global Arthritis Therapeutic Market, by Type

Psoriatic Arthritis Rheumatoid Arthritis Osteoarthritis Gout OthersGlobal Arthritis Therapeutic Market, by Drug Class

TNF Inhibitors Interleukin Inhibitors NSAIDs Corticosteroids Xanthine Oxidase Inhibitors OthersGlobal Arthritis Therapeutic Market by Route of Administration

Oral Parenteral TopicalGlobal Arthritis Therapeutic Market, by Distribution Channel

Hospital Pharmacies Retail Pharmacies Online PharmaciesGlobal Arthritis Therapeutic Market, by Region

Asia Pacific North America Europe Latin America Middle East AfricaGlobal Arthritis Therapeutic Market, Major Players

Pfizer Inc. Bristol Myers Squibb Abbvie Inc. Astrazeneca Pharma Ucb Pharma Genentech Janssen Pharmaceutical Immunex Corp. Medac Pharma Boehringer Ingelheim Novartis, Biogen Eli Lilly And Company Astellas Pharma Mallinckrodt Roche Vertex Pharmaceutical

MAJOR TOC OF THE REPORT

Chapter One: Arthritis Therapeutic Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Arthritis Therapeutic Market Competition, by Players

Chapter Four: Global Arthritis Therapeutic Market Size by Regions

Chapter Five: North America Arthritis Therapeutic Revenue by Countries

Chapter Six: Europe Arthritis Therapeutic Revenue by Countries

Chapter Seven: Asia-Pacific Arthritis Therapeutic Revenue by Countries

Chapter Eight: South America Arthritis Therapeutic Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Arthritis Therapeutic by Countries

Chapter Ten: Global Arthritis Therapeutic Market Segment by Type

Chapter Eleven: Global Arthritis Therapeutic Market Segment by Application

Chapter Twelve: Global Arthritis Therapeutic Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Arthritis Therapeutic Market Report at: https://www.maximizemarketresearch.com/market-report/global-arthritis-therapeutic-market/36112/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

View original post here:
Global Arthritis Therapeutic Market: Industry Analysis and forecast (2019 to 2026): By Type, Drug Class, Route of Administration, Distribution Channel...

Read More...

Polk doctors: Hand pain, stiffness from osteoarthritis can be treated – The Ledger

May 7th, 2020 7:46 am

People often deal with the discomfort of osteoarthritis by taking over-the-counter nonsteroidal anti-inflammatory drugs. Over time, if the pain worsens, they may find themselves taking those drugs in regular, increasing doses. That isnt good for older people, Polk experts say.

Your fingers feel stiff.

Parts of your hands often hurt.

Simple acts like opening a jar become more difficult or painful.

Its highly possible these problems stem from osteoarthritis of the hands.

Half of women and one-fourth of men experience osteoarthritis hand stiffness and pain by the time they reach 85, according to the Arthritis Foundation.

"Hand arthritis is extremely common in women," said Dr. Stuart Patterson, an orthopaedic surgeon in South Lakeland who specializes in disorders of the hand and other parts of the upper limb.

"We see it in men, but it typically occurs earlier in women."

People often deal with the discomfort initially by taking over-the-counter nonsteroidal anti-inflammatory drugs. Over time, if the pain worsens, they may find themselves taking those drugs in regular, increasing doses.

That isnt good for older people, local hand experts said.

"Once you get into your 60s, theyre not a safe drug," Patterson said.

"There are many interactions between these meds and supplements, as well as blood thinners (prescription as well as aspirin)," Dr. Ann Licht said in an email response to a question about whether its OK to rely on NSAIDS.

"People with high blood pressure and kidney problems may have more severe reactions to NSAIDS," added Licht, a Watson Clinic surgeon specializing in hand surgery.

Osteoarthritis is most common in the small joints of the fingers, closest to the nails and the base of the thumb, Licht said. It can occur on one side and spread to the other.

Gnarly fingers, bumps, finger deformities, joint stiffness and bone formations, often called bone spurs, are some physical signs that occur in advanced osteoarthritis of the hand, Patterson said.

Osteoarthritis causes protective cartilage at the end of bones to break down and wear away. Pain occurs as the bones rub together.

Surgery isnt all these surgeons and other hand specialists have to offer when that happens.

"Surgery is when youre disabled, either disabling pain or impairing your ability to do things," Patterson said, "when youre miserable and youve exhausted your non-surgical options."

Its helpful to see a hand surgeon before that stage to rule out other causes of pain, such as rheumatoid arthritis or carpal tunnel syndrome, he said.

Licht recommends seeing a hand specialist when medicines dont work, arent indicated or when deformities are starting.

"Steroid injections to the joints can be a lifesaver for patients who are either not ready for surgery cant take arthritis meds or the meds arent working," Licht said.

Occupational therapists have an important role in treating osteoarthritis of the hand. They work with patients on hand exercises, devices like splints or braces and pain relief such as warm paraffin.

Some therapists, mostly occupational but also some physical therapists, take extra training to become certified hand therapists.

"Our main goal in hand therapy is to preserve the hand," said Jennifer Castelli, occupational and certified hand specialist. "We focus on what they need and adapt it from there."

If a joint is overworked, it causes tension in the tissue around it, affecting the amount of pain. Joint damage also occurs.

Splints can keep the joint from moving so it has time to rest, Castelli said.

She and her husband, John, founded The Hand Rehabilitation Center of Florida. It has clinics in Winter Haven, Lakeland and Sebring.

Their Lakeland clinic has connecting space with Pattersons Central Florida Orthopaedic Surgery Associates. Patterson collaborates with Judie Johnson, another of the rehabilitation centers occupational therapists/certified hand specialists.

"Getting people in here early, before they develop horrible stiffness and horrible pain can help them learn helpful management skills," Johnson said.

Hand therapists can offer a variety of alternatives, including exercises to increase the hands range of motion and ways to do everyday activities that put less stress on the joints. Examples would be avoiding doing heavy pinching with the thumb and lifting pots with two hands instead of one, Johnson said.

Assistive devices can make it easier to open jars or hold a spoon.

"It doesnt fix the arthritis but it makes it so you hopefully can live with it," said Johnson, who has dealt with hand osteoarthritis of her own for 20 years.

Hand specialists can help "cut through the confusion" of the volume of devices and tools to find the ones most effective for individual patients, Patterson said.

"Even if two people have the same type of arthritis, their needs and medical history/conditions may make treatment very different," Licht said.

"Evaluation by a qualified hand surgeon can offer options and treatment solutions tailored to the individual."

When surgery is needed, patients and their surgeons decide between fusion or joint replacement. Which works best depends on the location of the damaged joint and, to some extent, what patients need to do with their hands.

Patterson said joint replacement doesnt do well in the small joints at the end of the fingers. He prefers fusion for them.

But fusion typically doesnt do as well at the base of the thumb, he said, or in the middle joint of the long and ring fingers. Those middle joints, he said, need to be able to bend and fusion prevents that.

Overall, joints are best fused if they arent "vital motion" joints, Licht said, while some need to be replaced to preserve or improve motion.

"Fusions are most reliable and require minimal rehab," she said. "Joint replacements require a compliant/committed patient as (they) usually require several months of rehab."

Robin Williams Adams can be reached at robinwadams99@yahoo.com

See original here:
Polk doctors: Hand pain, stiffness from osteoarthritis can be treated - The Ledger

Read More...

Plant viruses could be used to prevent and treat human autoimmune diseases – Mirage News

May 7th, 2020 7:46 am

Researchers have taken positive steps towards using plant virus-based particles for the treatment of human autoimmune diseases such as type 1 diabetes and rheumatoid arthritis.

Viruses are natural, self-assembling nano-scale structures that have been exploited in the fields of electronics, agriculture and medicine.

The genetically encoded coat proteins of virus nanoparticles (VNPs) can be reprogrammed to incorporate new sequences for specific functions. Plant viruses have the advantage in that they are unable to replicate in mammals making them safer for medical applications.

In this study led by the University of Verona, Italy, researchers explored whether VNPs engineered to display a specific protein sequence could help to prevent or treat type 1 diabetes and rheumatoid arthritis.

They used cowpea mosaic virus (CPMV) constructs developed in the Lomonossoff lab at the John Innes Centre. These VNPs displayed peptides associated with type 1 diabetes in order to modulate immune system response. The researchers also used other VNPs, engineering tomato bushy stunt virus with peptides associated with rheumatoid arthritis.

Using animal models to analyse immune system responses, they reveal that the re-engineered nanoparticles offered therapeutic benefits in both cases: protection against type 1 diabetes and improved symptoms of rheumatoid arthritis.

More pre-clinical and clinical trials will follow up this work. If successful it could pave the way for the development of plant viruses for the clinical treatment of human autoimmune diseases.

The research: Prevention and treatment of autoimmune diseases with plant virus nanoparticles appears in Science Advances.

Link:
Plant viruses could be used to prevent and treat human autoimmune diseases - Mirage News

Read More...

How Smart Technology Can Lead To Healthier Lives – HealthTechZone

May 6th, 2020 2:44 pm

As the saying goes, Knowledge is power. For you to make positive changes that will enable you tolive a healthier life, you need to learn and understand more about yourself. Technology has now made it easier for us to make informed choices.

There is a lot of data that has been collected and collated that reveals the truth to us. Using data analytics, we can be able to tell: how what we eat affects our longevity, how our surrounding affects our health, and what lifestyle changes we can make to boost our immunity from diseases.

In this article, we discuss how smart technology can help us live a healthier life.

Data Science

We can shrink the number of deaths caused by non-communicable diseases. This can be achieved by leveraging the power of data.

Data analytics can help us focus more on preventive measures rather than treating illnesses. With enough data on these diseases available, governments are able to formulate policies that will help prevent them from becoming prevalent.

Health Applications

To help change the focus from curative measures to preventive measures, individuals need to take more responsibility. More often, individuals are aware of what is beneficial to them; however, they have difficulty in altering their daily routines.

Smart technology can help you change your daily routine. There are more than 100,000 health applications available in the market. You can download one to your mobile phone that can guide you through.

For instance, you can get a mobile phone app that helps you to measure your physical activity. You can also get apps that will provide you with health-related advice.

Wearable Technology

Wearable technology has also contributed significantly in improving our healthcare systems. Combined with data analysis, this technology is already changing lives.

With wearable devices such as smartwatches, smart bracelets, among others, we can keep track of our health. The devices will alert you about where you are going and encourage you to be less sedentary.

Wearable technologies hold up a mirror to your lifestyle so that it becomes easier for you to initiate positive behavioral changes.

Smart Homes

With the advent of wireless technology, smart homes are quickly becoming a reality. Science has provided evidence that our homes and buildings are often unhealthy.

Some of the things that make our homes unhealthy include poor air quality and lighting. Thanks to smart home technology, you can now accurately measure all the essential variables.

Innovations in smart home technology enable us to practically solve these problems hence, allowing us to build homes that are healthy and sustainable.

Precision Medicine

Precision medicine uses your DNA to create individualized medical treatments. With precision medicine, it is possible to treat diseases that were previously costly and hard to manage. Examples of such diseases include cancer, neurological disorders, and other rare genetic conditions.

With precision medicine, novel treatments are created using genetics and other individual variables. This technology will significantly help us live healthier lives. For those individuals that are already living with conditions such as diabetes, cancer, among others, this technology will help them manage the conditions better.

Read more from the original source:
How Smart Technology Can Lead To Healthier Lives - HealthTechZone

Read More...

INTERVIEW | Leander Paes and the art of reinventing during lockdown – The New Indian Express

May 6th, 2020 2:44 pm

Express News Service

With tennis in 2020 almost lost due to COVID-19 & Olympics postponed, Leander Paes says he will reevaluate his career once everything is back to normal. In a chat with Indraneel Das, he gives a peek into life after retirement and challenges to stay fit...

Tennis legend Leander Paes is one of those few mortals on this planet who finds joy in everything. Tennis is definitely an inseparable part of him, but the lockdown has given him ample time to reinvent himself, pursue his passion that couldnt be done while on tours and focus on life after tennis. In a freewheeling interview, he reveals his future and recollects those moments that make him the Leander Paes. Wait he is not done with Olympics (that has been postponed to 2021), not as yet. Excerpts...

You have been associated with sports for over 30 years. Are you redefining the meaning of longevity?

I am blessed to have some great friendships in my career. With someone like Martina Hingis, Martina Navratilova, Roger Federer, Andre Agassi in my sport alone. In other sports, you look at Sachin Tendulkar, Bhaichung Bhutia, Vishi (Viswanathan) Anand to name a few, they have had very long careers. I have tried to learn from my peers and friends about that extra one per cent of diet, fitness, mental happiness, recovery and how to keep reinventing myself. I have been very blessed to have such a long career partly thanks to genetics from my parents but most importantly, the hard work that I have put in for over 30 years.

When you talk about reinventing yourself, do you mean motivating yourself all over again or setting new goals and targets?

All of the above. If you look at physical fitness. I remember my 33rd year, I felt I was quite exhausted at that time. I felt exhausted, thanks to the travel and the hours of training in the gym, on the tennis court; the long days that it takes to be a Grand Slam champion. I came back to my team. To my father and my fitness coach and my dietician and my mental trainer.

I reinvented my training system and then when I was 43, I had to reinvent again. Now one month shy of my 47th birthday, I have had to reinvent again with this lockdown period. So I think that its very important as a student of my craft or as a student of life to keep learning new things. I think that is one aspect of all the great champions in the world that I know. I have seen that they all reinvent themselves in all aspects of their lives.

Mentally, have you been very tough?

Yes, I think there are three different things. One is emotional fitness, two, physical fitness and three, there is tennis fitness the technical side, strategy; especially during times like these, emotional fitness and physical fitness are important.

Can you put in perspective postponement of Olympics vis-a-vis your career? You had said this would be your last Olympics.

This was my last season and it started off brilliantly at the Australian Open. I got a grand farewell there. Pune (Open) was a nice run. Bangalore was nice. Dubai, I got a wonderful farewell, Bangalore too. But then after the Davis Cup in Croatia, everything came to a standstill. We were fairly lucky in Croatia.

After we finished on Sunday and travelled back to India, ten odd days later, there was a huge earthquake there. So we got fairly lucky. As soon as I came back from Croatia, I was supposed to go back to Palm Springs in Miami, and it was cancelled. Then the French Open got postponed, Wimbledon cancelled.

I think, at the moment, I am concentrating on reinventing myself with other businesses. It is very hard that all our careers, our jobs have come to a standstill, especially in sport. Even when the lockdown opens up because we are a global sport, we have to travel all over the world 99 per cent of my work is outside India. I feel that in itself makes it very hard where even after the lockdown opens up.

I humbly feel that there is not going to be any tennis till January 2021. Hence I have got to reinvent myself this whole year. We are only sitting in May right now, we have got all of May, June, July, the whole summer, whole of American summer. We are probably going to miss all three Grand Slams, miss an Olympics this year. So with the Olympics postponed to 2021, I think post the lockdown or towards the end of the year, as things start opening up for tennis, we (my team and I) will only reevaluate then as to whether I should continue next year or not.

Is this the longest youve been away from the court?

I have been blessed with such a long career and have rewritten the history books multiple times over. I am blessed to have won so much in all the four Grand Slams. Australian Open I think I have won four times, French Open four times, Wimbledon five times and the US Open five times. In the Davis Cup, I have the world record. I have an Olympic medal.

The reason it was my one last roar this year was that I felt I had already achieved everything and there were few things to play for. To participate in three more Grand Slams to get to 100 is a lifetime of sweat and toil and hard work. So I think that when you look back at my career, it was blessed.

I will always be playing tennis. I will be playing tennis in some shape or form. Whether it is seniors or exhibition, whether it is world team tennis or league, whether it is playing for fun with my family. I will always have tennis in my day-to-day lifestyle. In terms of professional tennis, that is something we have to evaluate at the end of the year.

Away from tennis, are you pursuing any other professional career?

There is so much else to do. I cant really speak about it right now but there is so much my team planned for the last three, four years. Right now in one context, this lockdown has given a realisation that I have to reinvent myself. So its very nice that I get to spend time with my family, get to enjoy quality time with them. I have never spent this much time at home in one long stretch as I have always been working for the last 20 years.

Forty weeks a year travelling and touring non-stop. So I am really taking advantage of this time, spending time with my family. That being said, in terms of other opportunities, businesses and other passions I have had, my team has been working for the last four-five years to put things together. I am spending time to get that done. Because all of these are large projects and they need time and require my personal attention. I am enjoying that.

Any particular lockdown moment you would love to remember? Cooking...

I love to cook. I enjoy different kinds of cuisine obviously. Travelling on the tour it becomes a necessity and also you dont usually have a kitchen everywhere you go. So I specialise in pasta and salad. Breakfast is one of my favourite meals. I can eat breakfast morning, noon or night. And I love making different kinds of breakfast. When it comes to serious cooking, those are the things I am really passionate about.

When I finish with my tennis, I want to learn serious cooking. Take cooking classes. They have a Michelin chef cooking class. French patisserie is very interesting. The way they bake and make bread and pastries. There are so many fun things to do that in one context. I am really looking forward to that time as well. I always maximise whatever position I am in. I always make the best of it. No restaurant though. Cooking for my loved ones for sure.

How many hours do you train? Motivation an issue?

About three hours. Motivation is an issue. It is very difficult. It is something we all have to take stock of. Especially since we are not allowed to leave the house, we should ensure we get plenty of movement. Otherwise, we just sit down in one position on our phones, in front of the computer, or reading, watching Netflix and videos.

There is so much out there that it is distracting. It is really important to get movement. Even if it is walking in a living room. One room to the other. Freehand exercises, core exercises, yoga meditation or breathing, now is the time to do. All professional athletes are doing a lot of fitness exercises. Sustainability is important. You have to be mentally and emotionally fresh.

Even after lockdown, it will take a few weeks before professional sports are back. Plenty of time to sustain fitness levels but the fact is that we are not getting to play football, cricket, badminton or tennis now. Some tennis strokes might be a bit rusty. It might take a bit longer to fix that.

Which is your most cherished moment? Grand Slam wins, Davis Cup matches/records or the Olympic medal?

So many cherished moments! Its hard to pick. If I had to pick my Davis Cup wins, there are so many. If I have to pick every one of my Davis Cup wins, those were very special because I got to play for the tiranga (tricolour). I played for 1.3 billion people. Every one of my Grand Slam victories, all of them with different partners are very special. Then if you look at beating Pete Sampras in singles in New Haven in 1998; beating Roger Federer in singles in Indian Wells in 2001; winning the Newport Hall of Fame in 1998 was special.

If I have to choose the most important one, that would be the Olympic bronze. That is really, really special. The first time they introduced the (Olympic) play-offs, it was quite a tough. Was to meet Sampras in the first round and most of my peers were saying draw was bad luck. But somehow, I felt Atlanta was magic. I worked my whole life for it. The day before the first match, Sampras had pulled out, they put Richey Reneberg (USA) in. So I beat him, then Nicholas Pereira in the second, then Thomas Enqvist and beat Renzo Furlan in quarters.

In the semis, I injured my wrist. Andre Agassi played a passing shot when he was down 5-6 and 15-40, I pushed the ball to his backhand and he hit it as hard as he could right at my face. I felt I had every shot covered except that one. When he did, my hand hurt so badly that I didnt realise until later that I had a tear in my wrist tendon. That was a tough one. I had to come back two days later to play Fernando Meligeni, one of my friends from Brazil. To play him in the bronze play-off was tough because he was in good form. I was down a set to him and then I came back and won. After years of hard work and perseverance, I could emulate what my dad did, win an Olympic medal for India.Parents role in sportspersons development?

Parents have a huge role to play. That emotional fitness starts with parents. It is also important to know that the coaches the parents choose are very crucial. When you choose the right team, you choose the right coach, right fitness trainer. It is important to let the coaches do their job.

The parents do not have to be the coach. They dont have to be the fitness trainer or the physiotherapist. The parent needs to be the confidante. Parents can be the handling companion, support system. The unconditional love every parent gives is something every child needs. Its a huge support. I am what I am is because of my parents. I am so blessed. I have an unbelievable support system and Im lucky. Not only the genetics but all the skills they have taught.

On frying pan challenge and Mahesh Bhupathi

Its all about hand-eye coordination. Its not so difficult when you are a professional athlete. Mahesh Bhupathi and I have had some good banter. We stay in touch and its nice that we can communicate and bring some happiness to people especially in a time like this when it is needed.

See the rest here:
INTERVIEW | Leander Paes and the art of reinventing during lockdown - The New Indian Express

Read More...

Precision Medicine Software Market to See Massive Growth by 2026| Syapse, Allscripts, Qiagen, Roper Technologies, Fabric Genomics, Foundation…

May 6th, 2020 2:44 pm

Global Precision Medicine Software Market: Trends Estimates High Demand by 2027

The Precision Medicine Software Market 2020 report includes the market strategy, market orientation, expert opinion and knowledgeable information. The Precision Medicine Software Industry Report is an in-depth study analyzing the current state of the Precision Medicine Software Market. It provides a brief overview of the market focusing on definitions, classifications, product specifications, manufacturing processes, cost structures, market segmentation, end-use applications and industry chain analysis. The study on Precision Medicine Software Market provides analysis of market covering the industry trends, recent developments in the market and competitive landscape.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Precision Medicine Software market. All findings and data on the global Precision Medicine Software market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Precision Medicine Software market available in different regions and countries.

The final report will add the analysis of the Impact of Covid-19 in this report Precision Medicine Software industry.

Some of the companies competing in the Precision Medicine Software markets are: Syapse, Allscripts, Qiagen, Roper Technologies, Fabric Genomics, Foundation Medicine, Sophia Genetics, PierianDx, Human Longevity, Translational Software, Gene42, Inc, Lifeomic Health

Get a Free Sample [emailprotected] https://www.reportsandmarkets.com/sample-request/global-precision-medicine-software-market-2019-by-company-regions-type-and-application-forecast-to-2024

The report scrutinizes different business approaches and frameworks that pave the way for success in businesses. The report used Porters five techniques for analyzing the Precision Medicine Software Market; it also offers the examination of the global market. To make the report more potent and easy to understand, it consists of info graphics and diagrams. Furthermore, it has different policies and development plans which are presented in summary. It analyzes the technical barriers, other issues, and cost-effectiveness affecting the market.

Global Precision Medicine Software Market Research Report 2020 carries in-depth case studies on the various countries which are involved in the Precision Medicine Software market. The report is segmented according to usage wherever applicable and the report offers all this information for all major countries and associations. It offers an analysis of the technical barriers, other issues, and cost-effectiveness affecting the market. Important contents analyzed and discussed in the report include market size, operation situation, and current & future development trends of the market, market segments, business development, and consumption tendencies. Moreover, the report includes the list of major companies/competitors and their competition data that helps the user to determine their current position in the market and take corrective measures to maintain or increase their share holds.

What questions does the Precision Medicine Software market report answer pertaining to the regional reach of the industry

The report claims to split the regional scope of the Precision Medicine Software market into North America, Europe, Asia-Pacific, South America & Middle East and Africa. Which among these regions has been touted to amass the largest market share over the anticipated duration

How do the sales figures look at present How does the sales scenario look for the future

Considering the present scenario, how much revenue will each region attain by the end of the forecast period

How much is the market share that each of these regions has accumulated presently

How much is the growth rate that each topography will depict over the predicted timeline

A short overview of the Precision Medicine Software market scope:

Global market remuneration

Overall projected growth rate

Industry trends

Competitive scope

Product range

Application landscape

Supplier analysis

Marketing channel trends Now and later

Sales channel evaluation

Market Competition Trend

Market Concentration Rate

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

Chapter 1:Precision Medicine Software Market Overview

Chapter 2: Global Economic Impact on Industry

Chapter 3:Precision Medicine Software Market Competition by Manufacturers

Chapter 4: Global Production, Revenue (Value) by Region

Chapter 5: Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6: Global Production, Revenue (Value), Price Trend by Type

Chapter 7: Global Market Analysis by Application

Chapter 8: Manufacturing Cost Analysis

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Precision Medicine Software Market Effect Factors Analysis

Chapter 12: GlobalPrecision Medicine Software Market Forecast to 2027

Get Complete Report @ https://www.reportsandmarkets.com/sample-request/global-precision-medicine-software-market-2019-by-company-regions-type-and-application-forecast-to-2024

About Us:

Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Are you mastering your market? Do you know what the market potential is for your product, who the market players are and what the growth forecast is? We offer standard global, regional or country specific market research studies for almost every market you can imagine.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

The rest is here:
Precision Medicine Software Market to See Massive Growth by 2026| Syapse, Allscripts, Qiagen, Roper Technologies, Fabric Genomics, Foundation...

Read More...

Adrenomyeloneuropathy Treatment Market Size, Key Trends, Challenges and Standardization, Research, Key Players, Economic Impact and Forecast to 2026|…

May 6th, 2020 2:44 pm

Latest Report On Adrenomyeloneuropathy Treatment Market including Market Landscape, and Market size, Revenues by players, Revenues by regions, Average prices, Competitive landscape, market Dynamics and industry trends and developments during the forecast period.

The global Adrenomyeloneuropathy Treatment market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global Adrenomyeloneuropathy Treatment market. The research study comes out as a compilation of useful guidelines for players to secure a position of strength in the global market. The authors of the report profile leading companies of the global Adrenomyeloneuropathy Treatment market, Also the details about important activities of leading players in the competitive landscape.

Key companies operating in the global Adrenomyeloneuropathy Treatment market include: :, Ascend Biopharmaceuticals, Novadip Biosciences, Eureka Therapeutics, Human Longevity, Regeneus, Allogene Therapeutics, BioRestorative Therapies, Immatics Biotechnologies, NewLink Genetics, Cytori Therapeutics, Talaris Therapeutics

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1664172/global-adrenomyeloneuropathy-treatment-market

The report predicts the size of the global Adrenomyeloneuropathy Treatment market in terms of value and volume for the forecast period 2020-2026. As per the analysis provided in the report, the global Adrenomyeloneuropathy Treatment market is expected to rise at a CAGR of xx % between 2020 and 2026 to reach a valuation of US$ xx million/billion by the end of 2026. In 2020, the global Adrenomyeloneuropathy Treatment market attained a valuation of US$ XX million/billion. The market researchers deeply analyze the global Adrenomyeloneuropathy Treatment industry landscape and the future prospects it is anticipated to create

Segmental Analysis

The report has classified the global Adrenomyeloneuropathy Treatment industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Adrenomyeloneuropathy Treatment manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Adrenomyeloneuropathy Treatment industry.

Global Adrenomyeloneuropathy Treatment Market Segment By Type:

, Steroid Replacement Therapy, Stem Cell Transplant By the end users,

Global Adrenomyeloneuropathy Treatment Market Segment By Application:

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Adrenomyeloneuropathy Treatment market in 2020. COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future. This report also analyses the impact of Coronavirus COVID-19 on the Adrenomyeloneuropathy Treatment industry. Based on our recent survey, we have several different scenarios about the Adrenomyeloneuropathy Treatment YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Adrenomyeloneuropathy Treatment will reach xx in 2026, with a CAGR of xx% from 2020 to 2026. Global Adrenomyeloneuropathy Treatment market: Drivers and Restraints This section covers the various factors driving the global Adrenomyeloneuropathy Treatment market. To understand the growth of the market it is important to analyze the various drivers present the market. It provides data by value and volume of different regions and their respective manufacturers. This data will elaborate on the market share occupied by them, predict their revenue concerning strategies, and how they will grow in the future. After explaining the drivers, the report further evaluates the new opportunities and current trends in the market. Market restraints are factors hampering market growth. Studying these factors is equally pivotal as they help a reader need understand the weaknesses of the market. Global Adrenomyeloneuropathy Treatment market: Segment Analysis The global Adrenomyeloneuropathy Treatment market is split into two segments, type, and application. The product type briefs on the various types of products available in the market. The report also provides data for each product type by revenue for the forecast time period. It covers the price of each type of product. The other segment on the report, application, explains the various uses of the product and end-users. In the report, the researchers have also provided revenue according to the consumption of the product. Global Adrenomyeloneuropathy Treatment market: Regional Analysis The major regions covered in the report are North America, Europe, China, Rest of Asia Pacific, Central & South America, Middle East & Africa, etc. It includes revenue analysis of each region for the year 2015 to 2026. Global Adrenomyeloneuropathy Treatment market: Key Players The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market. By the therapy, the market is primarily split into, Steroid Replacement Therapy, Stem Cell Transplant By the end users, Hospitals, Clinics, Ambulatory Surgical Centers, Others

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Adrenomyeloneuropathy Treatment industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Adrenomyeloneuropathy Treatment market include: :, Ascend Biopharmaceuticals, Novadip Biosciences, Eureka Therapeutics, Human Longevity, Regeneus, Allogene Therapeutics, BioRestorative Therapies, Immatics Biotechnologies, NewLink Genetics, Cytori Therapeutics, Talaris Therapeutics

Key questions answered in the report:

Enquire for Customization in the report @ https://www.qyresearch.com/customize-request/form/1664172/global-adrenomyeloneuropathy-treatment-market

TOC

1 Market Overview of Adrenomyeloneuropathy Treatment1.1 Adrenomyeloneuropathy Treatment Market Overview1.1.1 Adrenomyeloneuropathy Treatment Product Scope1.1.2 Market Status and Outlook1.2 Global Adrenomyeloneuropathy Treatment Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Adrenomyeloneuropathy Treatment Market Size by Region (2015-2026)1.4 Global Adrenomyeloneuropathy Treatment Historic Market Size by Region (2015-2020)1.5 Global Adrenomyeloneuropathy Treatment Market Size Forecast by Region (2021-2026)1.6 Key Regions Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.1 North America Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.2 Europe Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.3 China Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.4 Rest of Asia Pacific Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.5 Latin America Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.6 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.7 Coronavirus Disease 2019 (Covid-19): Adrenomyeloneuropathy Treatment Industry Impact1.7.1 How the Covid-19 is Affecting the Adrenomyeloneuropathy Treatment Industry

1.7.1.1 Adrenomyeloneuropathy Treatment Business Impact Assessment Covid-19

1.7.1.2 Supply Chain Challenges

1.7.1.3 COVID-19s Impact On Crude Oil and Refined Products1.7.2 Market Trends and Adrenomyeloneuropathy Treatment Potential Opportunities in the COVID-19 Landscape1.7.3 Measures / Proposal against Covid-19

1.7.3.1 Government Measures to Combat Covid-19 Impact

1.7.3.2 Proposal for Adrenomyeloneuropathy Treatment Players to Combat Covid-19 Impact 2 Adrenomyeloneuropathy Treatment Market Overview by Therapy2.1 Global Adrenomyeloneuropathy Treatment Market Size by Therapy: 2015 VS 2020 VS 20262.2 Global Adrenomyeloneuropathy Treatment Historic Market Size by Therapy (2015-2020)2.3 Global Adrenomyeloneuropathy Treatment Forecasted Market Size by Therapy (2021-2026)2.4 Steroid Replacement Therapy2.5 Stem Cell Transplant 3 Adrenomyeloneuropathy Treatment Market Overview by Therapy3.1 Global Adrenomyeloneuropathy Treatment Market Size by End Users: 2015 VS 2020 VS 20263.2 Global Adrenomyeloneuropathy Treatment Historic Market Size by End Users (2015-2020)3.3 Global Adrenomyeloneuropathy Treatment Forecasted Market Size by End Users (2021-2026)3.4 Hospitals3.5 Clinics3.6 Ambulatory Surgical Centers3.7 Others 4 Global Adrenomyeloneuropathy Treatment Competition Analysis by Players4.1 Global Adrenomyeloneuropathy Treatment Market Size (Million US$) by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Adrenomyeloneuropathy Treatment as of 2019)4.3 Date of Key Manufacturers Enter into Adrenomyeloneuropathy Treatment Market4.4 Global Top Players Adrenomyeloneuropathy Treatment Headquarters and Area Served4.5 Key Players Adrenomyeloneuropathy Treatment Product Solution and Service4.6 Competitive Status4.6.1 Adrenomyeloneuropathy Treatment Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 Ascend Biopharmaceuticals5.1.1 Ascend Biopharmaceuticals Profile5.1.2 Ascend Biopharmaceuticals Main Business and Companys Total Revenue5.1.3 Ascend Biopharmaceuticals Products, Services and Solutions5.1.4 Ascend Biopharmaceuticals Revenue (US$ Million) (2015-2020)5.1.5 Ascend Biopharmaceuticals Recent Developments5.2 Novadip Biosciences5.2.1 Novadip Biosciences Profile5.2.2 Novadip Biosciences Main Business and Companys Total Revenue5.2.3 Novadip Biosciences Products, Services and Solutions5.2.4 Novadip Biosciences Revenue (US$ Million) (2015-2020)5.2.5 Novadip Biosciences Recent Developments5.3 Eureka Therapeutics5.5.1 Eureka Therapeutics Profile5.3.2 Eureka Therapeutics Main Business and Companys Total Revenue5.3.3 Eureka Therapeutics Products, Services and Solutions5.3.4 Eureka Therapeutics Revenue (US$ Million) (2015-2020)5.3.5 Human Longevity Recent Developments5.4 Human Longevity5.4.1 Human Longevity Profile5.4.2 Human Longevity Main Business and Companys Total Revenue5.4.3 Human Longevity Products, Services and Solutions5.4.4 Human Longevity Revenue (US$ Million) (2015-2020)5.4.5 Human Longevity Recent Developments5.5 Regeneus5.5.1 Regeneus Profile5.5.2 Regeneus Main Business and Companys Total Revenue5.5.3 Regeneus Products, Services and Solutions5.5.4 Regeneus Revenue (US$ Million) (2015-2020)5.5.5 Regeneus Recent Developments5.6 Allogene Therapeutics5.6.1 Allogene Therapeutics Profile5.6.2 Allogene Therapeutics Main Business and Companys Total Revenue5.6.3 Allogene Therapeutics Products, Services and Solutions5.6.4 Allogene Therapeutics Revenue (US$ Million) (2015-2020)5.6.5 Allogene Therapeutics Recent Developments5.7 BioRestorative Therapies5.7.1 BioRestorative Therapies Profile5.7.2 BioRestorative Therapies Main Business and Companys Total Revenue5.7.3 BioRestorative Therapies Products, Services and Solutions5.7.4 BioRestorative Therapies Revenue (US$ Million) (2015-2020)5.7.5 BioRestorative Therapies Recent Developments5.8 Immatics Biotechnologies5.8.1 Immatics Biotechnologies Profile5.8.2 Immatics Biotechnologies Main Business and Companys Total Revenue5.8.3 Immatics Biotechnologies Products, Services and Solutions5.8.4 Immatics Biotechnologies Revenue (US$ Million) (2015-2020)5.8.5 Immatics Biotechnologies Recent Developments5.9 NewLink Genetics5.9.1 NewLink Genetics Profile5.9.2 NewLink Genetics Main Business and Companys Total Revenue5.9.3 NewLink Genetics Products, Services and Solutions5.9.4 NewLink Genetics Revenue (US$ Million) (2015-2020)5.9.5 NewLink Genetics Recent Developments5.10 Cytori Therapeutics5.10.1 Cytori Therapeutics Profile5.10.2 Cytori Therapeutics Main Business and Companys Total Revenue5.10.3 Cytori Therapeutics Products, Services and Solutions5.10.4 Cytori Therapeutics Revenue (US$ Million) (2015-2020)5.10.5 Cytori Therapeutics Recent Developments5.11 Talaris Therapeutics5.11.1 Talaris Therapeutics Profile5.11.2 Talaris Therapeutics Main Business and Companys Total Revenue5.11.3 Talaris Therapeutics Products, Services and Solutions5.11.4 Talaris Therapeutics Revenue (US$ Million) (2015-2020)5.11.5 Talaris Therapeutics Recent Developments 6 North America Adrenomyeloneuropathy Treatment by Players and by End Users6.1 North America Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)6.2 North America Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 7 Europe Adrenomyeloneuropathy Treatment by Players and by End Users7.1 Europe Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)7.2 Europe Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 8 China Adrenomyeloneuropathy Treatment by Players and by End Users8.1 China Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)8.2 China Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 9 Rest of Asia Pacific Adrenomyeloneuropathy Treatment by Players and by End Users9.1 Rest of Asia Pacific Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)9.2 Rest of Asia Pacific Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 10 Latin America Adrenomyeloneuropathy Treatment by Players and by End Users10.1 Latin America Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)10.2 Latin America Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 11 Middle East & Africa Adrenomyeloneuropathy Treatment by Players and by End Users11.1 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)11.2 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 12 Adrenomyeloneuropathy Treatment Market Dynamics12.1 Industry Trends12.2 Market Drivers12.3 Market Challenges12.4 Porters Five Forces Analysis 13 Research Finding /Conclusion 14 Methodology and Data Source 14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Disclaimer14.4 Author List

About Us

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Here is the original post:
Adrenomyeloneuropathy Treatment Market Size, Key Trends, Challenges and Standardization, Research, Key Players, Economic Impact and Forecast to 2026|...

Read More...

Semiconductor Laser Therapeutic Equipment Market Detail Analysis focusing on Application, Types and Regional Outlook – AlgosOnline

May 6th, 2020 2:42 pm

Market Study Report, LLC, adds a thorough analysis of the ' Semiconductor Laser Therapeutic Equipment market', offering a comprehensive report emphasizing every vital aspect of the business vertical. The study has collectively presented refined data characterized by market valuation, SWOT analysis, market participants, regional segmentation, and revenue forecasts, enabling stakeholders to make logical business decisions.

The research report on Semiconductor Laser Therapeutic Equipment market is a comprehensive analysis of this business space and entails all the key aspects of the industry including net revenue estimates, present renumeration, periodic deliverables, segmental share, market size, and market trends.

Request a sample Report of Semiconductor Laser Therapeutic Equipment Market at:https://www.marketstudyreport.com/request-a-sample/2470854

A brief assessment of the behavior pattern of the Semiconductor Laser Therapeutic Equipment market over the forecast timeline has been cited in the report. Critical parameters such as growth drivers as well the expected growth rate followed during the study period are also documented in the report. It further elaborates on the potential growth aspects and restraints of this industry.

Main highlights of Semiconductor Laser Therapeutic Equipment market report:

Geographical scrutiny of the Semiconductor Laser Therapeutic Equipment market:

Semiconductor Laser Therapeutic Equipment Market Segmentation:

Key insights presented in the report with respect to the regional outlook:

A thorough analysis of Semiconductor Laser Therapeutic Equipment market with respect to the product landscape and application spectrum:

Product landscape:

Product types: Opthalmology, Dermatology, Gynecology, Dentistry, Urology, Cardiovascular and Others

Ask for Discount on Semiconductor Laser Therapeutic Equipment Market Report at:https://www.marketstudyreport.com/check-for-discount/2470854

Main insights presented in the report:

Application landscape: IIII

Major discoveries of the report:

Other takeaways of Semiconductor Laser Therapeutic Equipment market report:

Additional insight on the competitive outlook of the Semiconductor Laser Therapeutic Equipment market:

Vendor base of the industry: Sirona Dental Systems GmbH, WON TECH, Lumenis Inc., PHYSIOMED ELEKTROMEDIZIN AG, Biolase, Dornier MedTech GmbH, Cutera, IRIDEX Corporation, Quanta System S.p.A, Cynosure, L.H.H. Medical, Shenzhen Tianjiquan, Zhengan Medical, Shandong Shensi, Medicen, Guangdun, Kangjiantong, Wuhan HNC, Helsen, Transverse Industries and Shenzhen GSD

Vital parameters which define the competitive landscape of the Semiconductor Laser Therapeutic Equipment market:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-semiconductor-laser-therapeutic-equipment-market-growth-2020-2025

Related Reports:

1. Global Assistive Technologies for Visual Impairment Market Growth 2020-2025Read More: https://www.marketstudyreport.com/reports/global-assistive-technologies-for-visual-impairment-market-growth-2020-2025

2. Global Pre-Filled Syringe (Prefilled Syringe) Market Growth 2020-2025Read More: https://www.marketstudyreport.com/reports/global-pre-filled-syringe-prefilled-syringe-market-growth-2020-2025

Read More Reports On: https://www.marketwatch.com/press-release/thin-and-ultra-thin-film-market-size-2020-industry-growth-competitive-analysis-future-prospects-and-forecast-2025-2020-04-30

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Original post:
Semiconductor Laser Therapeutic Equipment Market Detail Analysis focusing on Application, Types and Regional Outlook - AlgosOnline

Read More...

This is the new unit planned for Chorley Hospital and what it will be used for – Chorley Guardian

May 6th, 2020 2:42 pm

The 17.5m facility would provide three new theatres two reserved for ophthalmology and a third for other procedures which do not require overnight admission.

An extra outpatients department and day ward also feature in the proposed four-storey building on the Euxton Lane site.

Lancashire Teaching Hospitals NHS Foundation Trust (LTH) is seeking planning permission for the development from Chorley Council and has described the project as exciting.

The Local Democracy Reporting Service understands that the scheme is unrelated to the forthcoming public consultation over the future of the accident and emergency unit at the site, which also has implications for how the rest of the hospital would be used in future.

In January, it emerged that two out of the three options likely to form the basis of that consultation recommended that Chorley Hospital should become a centre of excellence for routine, pre-planned care the like of which could be accommodated by the planned new facility.

However, it is believed that the project will go ahead regardless of the outcome of that exercise, which has itself now been delayed by the coronavirus outbreak.

If permission is granted, the new unit is expected to be open by October 2021 and will bring all opthalmology servies under one roof on the site.

Existing facilities at the Royal Preston would be unaffected by the plans and continue to operate as they do currently.

Dr Geraldine Skailes, medical director at LTH, said: We are really pleased to be able to provide this additional facility which will help us to improve patient experience.

The unit will include a dedicated outpatient and diagnostic space as well as three additional theatres to provide extra capacity for patients requiring a variety of day case procedures.

The new unit will connect to the main hospital on the first and second floors with respective links to the existing outpatients department and theatres.

According to the planning application, staff facilities will be located on the ground floor, with the remaining space earmarked for future hospital expansion. The fourth floor will house the plant room.

The facility is set to be built on a part of the site currently partially occupied by a storage unit for sterilisation and decontamination, which will be relocated.

The development will see an existing staff car park expanded by 64 spaces to accommodate a total of 174 vehicles.

Highways England have requested that consideration of the application be deferred until the trust has provided further information about expected vehicle trips to the unit, so that their potential impact on junction eight of the M61 motorway can be assessed.

Continued here:
This is the new unit planned for Chorley Hospital and what it will be used for - Chorley Guardian

Read More...

Personalized Medicine Complicated by Overlapping Versions of Our Genetic History – Technology Networks

May 6th, 2020 2:41 pm

The massive international effort to map the entire human genome, completed in 2003, opened a new field we now know as personalized medicine.

The breakthrough, which identified the location and function of every human gene, offered the promise of medical care tailored specifically to individual patients, based on their personal genetic makeup.

When researchers identified a gene associated with a 44 per cent risk of breast cancer in women, for example, it seemed that protecting them might be as simple as deactivating that gene.

But the promise of such personalized medicine has not fully materialized, say two McMaster researchers, because the full sophistication of the genetic blueprint has a more complex and far-reaching influence on human health than scientists had first realized.

In the hope of integrating genetics more closely with medical practice, McMaster evolutionary biologists Rama Singh and Bhagwati Gupta have carried out an exhaustive and critical review of decades of research in their field. They lay out their conclusions inan articlepublished today in the Nature Partner JournalGenomic Medicine.

The biochemical pathway that shapes evolution is dense with inherited redundancies, they explain. Genetic information from our ancestors trails along forever in an incremental physical record that interacts significantly with our own most recently evolved and internally complex genetic network, which in turn interacts with the environment, creating almost infinite combinations and potential health outcomes.

Individual genes do not determine sickness or health on their own, the authors say, but act in concert with groups of other genes all in various stages of mutation in ways that are just beginning to be understood.

Our bodies have an immense ability to change and to cope with issues that arise. Context matters in our genome, Gupta says. Even a simple single mutation can have a profound effect on the body, when acting in combination with others.

The scientists conclude that precision medicine is still critical to the future of medicine, but that the same technology that identified the necessary complexity of the genome also needs to be applied to the entire blueprint including the unnecessary elements creating a longer, more complicated road to the same destination.

Any disease we see is a result of the interactions between necessary and unnecessary complexity, says Gupta.

Nature does not go back in time. It goes forward, and as it encounters challenges, it comes up with solutions.

Our genes carry the history of all the changes that have occurred over many generations. It may not be necessary to our function today, but it is embedded in our genes.

Complexity is not a curse. Its a reflection of our evolutionary history, and it needs to be recognized as an important part of the body that medicine is trying to treat, Singh says. Beyond personalized medicine, complexity bears on the evolution of life itself.

Reference:Rama S. Singh, Bhagwati P. Gupta. Genes and genomes and unnecessary complexity in precision medicine. npj Genomic Medicine, 2020; 5 (1) DOI: 10.1038/s41525-020-0128-1.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the article here:
Personalized Medicine Complicated by Overlapping Versions of Our Genetic History - Technology Networks

Read More...

Exploring the Ethics of Genetic Testing: What Does Consent Mean? – Technology Networks

May 6th, 2020 2:41 pm

As with any medical procedure, to undergo genetic testing, informed consent must be given.According to the National Institutes of Health, informed consent (in the context of genetic testing) is the process of making sure that, wherever possible, a patient fully understands:

With this information, a patient can make an educated, voluntary choice i.e. they are informed to a level such that they can provide consent. This is usually a legal and ethical requirement in medicine.Whilst this might seem like a relatively simple concept, for genetic testing, informed consent suddenly becomes a whole lot more complex. Bioethicists, experts in the ethical practice of biology and medicine, often use case studies to explore these complexities and to discuss potential solutions to the dilemmas arising from them.

Jodie is a 28-year-old woman who is thinking about having children. However, she has a family history of limb-girdle muscular dystrophy and is considering undergoing genetic screening to determine if she is a carrier of any variants (a.k.a. mutations in her genome) associated with the disease.

Genetic Counselor Margarita Raygada, Ph.D., explains the role of a genetic counselor in cancer care and shares the benefits and implications of genetic testing for patients and their families.Genetic counselors are individuals educated in both medical genetics and counseling. This gives them the expertise to provide patients with the knowledge required to give consent, but also to offer guidance and support. As such, they are most likely the person who will be responsible for gaining informed consent from the patient.

Laura Hercher, Director of Research in Human Genetics at Sarah Lawrence College, has almost 20 years experience working as a genetic counselor. She emphasizes that the role of counseling goes far beyond testing alone:

Genetic counseling is about more than genetic testing. It can obviously be about that, and a genetic counselor would be a good person to discuss genetic testing with, but we meet with people where genetic testing isn't on the table at all.

I think that there is an element of education in many genetic counseling sessions or interpretation but also in many circumstances, theres what we call establishing a therapeutic relationship, where you do the counseling side of it.

Continuing on this theme, Hercher points out a key aspect of genetic counseling and something which is crucial to the consent process but often forgotten amongst the hype surrounding genetic testing.

We [genetic counselors] don't take for granted that somebody will want genetic testing. They have the right to say no these are shared norms in genetics in the UK and the US.

However, in Jodies case, she has expressed interest in genetic testing. How does a genetic counselor go about establishing informed consent for this?

You have to consider both of these two very basic things, Hercher begins. Make sure the person has an understanding of what genetic testing may tell them and also have an understanding of what genetic testing may not tell them.

These are very important to understand because, number one, you don't want someone to walk away from the experience saying, "Okay, great, I've been tested. I don't have a disease, if that isn't comprehensive.

Number two, we want to talk about what the test will show the patient, both in terms of setting up correct expectations that's consent but also by identifying additional things they might find out that are not necessarily the goals of testing.

The blood sample provided by Jodie undergoes whole exome sequencing. Upon sequence analysis, its found that Jodie does not have any of the variants currently associated with limb-girdle muscular dystrophy. However, the person analyzing the data also checks for other common disease-associated variants. They discover that Jodie has a mutation in BRCA2 that puts her at a higher risk of developing breast and/or ovarian cancer.

The discovery described above is known as a secondary finding, meaning that whilst its identification may not have been the main goal of the test, its presence was actively sought. This is different to an incidental finding, although the terms are often used interchangeably.The potential for secondary findings demonstrates how consent in genetic testing isnt as simple as a single yes or no answer. The decision to actively look for other variants and have them reported back provides an additional layer of consideration to the consent process.

In 2013, the American College of Medical Genetics and Genomics (AMCG) published recommendations for the responsible handling of incidental findings emerging from clinical exome or genome sequencing. This includes clinicians being responsible for alerting patients to the possibility that sequencing could result in incidental findings, and that these may warrant further investigation.1A proper informed consent for genetic testing would give the person a notion of what they might encounter as a part of testing, and what choices they have, about what [testing or results] they can get and what not to get, if there are choices available in the setting in which you're operating.

Jodie doesnt just have a decision to make about whether or not she wants the test, she also has to consider what results she would want reported back to her. The availability of choice is an important one because of the potential implications, both physically and mentally, of being given information you werent expecting or didnt want to receive.

Jodies results show that she, and potentially her first-degree relatives, are at a high risk of developing breast and/or ovarian cancer. Although it isnt a guarantee that she would develop those diseases, this knowledge could impact upon decisions she makes about her healthcare. For people carrying a disease-associated BRCA mutation, preventative, albeit drastic, surgical measures may be available, including mastectomies and oophorectomies.

Preventative surgery, or even just knowing that you may develop a disease can also take an emotional toll. In addition, a patient could find out that they have variation that means they will develop a condition at some point in their lifetime, such as Huntingtons disease. This may have an impact on mental health if there are currently very limited or no treatment options for the condition diagnosed, although further and continual research needs to be conducted to assess the extent of such an impact.

Secondary findings can also emerge with advances in research; a variant that may not have been considered a pathogenic variant before could be considered so in the future, or vice versa. Patients like Jodie would need to think about whether they would want to be re-contacted with new or updated information.

Thats a lot of factors for someone to consider before consenting. How can we simplify consent to account for all of those decisions and outcomes, if its even possible?

This requires time something which the healthcare system doesnt always have enough of. How do we create a process that works for both clinicians and patients?

The answers people are coming up with tend to be that we need better tools, Hercher tells me. And that includes online or digital tools that would allow people to interact with the information. You know, if you sit somebody down and spout off 15 minutes worth of information, dense information, you're not doing anything for them.

So, what's needed to improve the situation is new tools that allow people to tackle it over time, at their own pace, exploring what they want to and when. That would optimize the situation for both the caregiver and the patient. And allow them to go back to it [the information] to refresh their memory and so on. The optimal consent process is not "let's decide everything we can fit into this space of time consent, optimally, is an ongoing process.

Research conducted in the UK seems to agree. A recent report from the Joint Committee on Genomics in Medicine sums it up nicely:Consent may be more appropriately seen as an ongoing conversation that needs updating and clarifying where necessary, rather than as a single historical event that needs to be revisited.Reference

Go here to read the rest:
Exploring the Ethics of Genetic Testing: What Does Consent Mean? - Technology Networks

Read More...

Gene Variants That Protect Against Glaucoma Discovered – Technology Networks

May 6th, 2020 2:41 pm

Glaucoma is an eye disease affecting almost 80 million people and is the second leading cause of blindness worldwide.

Glaucoma results in progressive damage to the optic nerve head, which leads to a corresponding visual field loss and when severe, blindness. The pressure within the eye (intraocular pressure) is the only modifiable risk factor for glaucoma.

Glaucoma has a clear genetic component and tens of common genetic variants affecting intraocular pressure and/or glaucoma risk have been identified. The clinical impact of these results has, however, thus far been negligible.

In this study, published in the journal PLOS Genetics, researchers searched for less common genetic variants which might lower intraocular pressure and protect from glaucoma and focused on those with a clear effect on the function of the corresponding protein product. Such variants have particularly high therapeutic potential since they would highlight a specific gene and a genetic modification that protects from disease.

The results of the study are based on two big European cohorts with large-scale genome and health information data available. Altogether more than 514,000 individuals from the UK Biobank and the FinnishFinnGenstudies were examined. Both cohorts include thousands of individuals with a glaucoma diagnosis. Furthermore, over 120 000 UK Biobank participants have participated in the intraocular pressure measurement tests.

Both study cohorts provided independent, complementary and convincing evidence for the role of theANGPTL7gene in glaucoma. UK Biobank participants carried several rare genetic changes that were shown to reduce intraocular pressure, while FinnGen study provided very strong evidence of another variant specific to the Finnish population which significantly decreased glaucoma risk.

The variant we identified is more than 50 times more common in the Finnish population than elsewhere in the world. In fact, more than 8% of Finns carry it and have a substantially reduced risk of glaucoma. This again demonstrates how the population history of the Finns makes it much easier to identify clinically important genetic variants, said ProfessorMark Dalyfrom the Institute for Molecular Medicine Finland (FIMM), University of Helsinki who co-led the study.

With clinic-based recruitment focused on several areas including ophthalmology, and with more than 30 % of the participants being above age 70, FinnGen is particularly well-powered for aging-associated endpoints.

We often think of the body as a machine whereby taking a single bolt out of that machine and something could go wrong. In this study that hypothetical bolt made the machine work even better by protecting human individuals from glaucoma. Our results highlight the benefits of multi-cohort analysis for the discovery of rare protein-altering variants in common diseases, and ANGPTL7 provides the best therapeutic hypothesis out there for glaucoma, saidManuel Rivas,assistant professor of biomedical data science, Stanford Universitys School of Medicine, who co-led the study.

Importantly, cohorts such as FinnGen and UK Biobank make it possible for the researchers to assess whether the identified protective variants increase the risk of some other condition.

Using the comprehensive health information in the two population cohorts, we assessed the potential impacts of rare genetic variants inANGPTL7on a spectrum of human disorders. We did not find any severe medical consequences that would be of obvious concern in developing a therapeutic to mimic the effect of these alleles, saidYosuke Tanigawa,doctoral student, Stanford Universitys School of Medicine, the first author of the study.

Better understanding of the genetic and pathological mechanism behind intraocular pressure can open up new ways of preventing or treating glaucoma. In this case, the genetic findings support inhibition or lowering the amount of ANGPTL7 as a potentially safe and effective therapeutic strategy for glaucoma.

Our results position angiopoietin like 7 as an appealing and safe target for glaucoma therapies. If a drug can be developed that mimics the protective effect of these mutations, intraocular pressure in at-risk individuals could be lowered, saidMark Daly.

Reference:Tanigawa et al. (2020).Rare protein-altering variants in ANGPTL7 lower intraocular pressure and protect against glaucoma. PLOS Genetics. DOI: https://doi.org/10.1371/journal.pgen.1008682.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more:
Gene Variants That Protect Against Glaucoma Discovered - Technology Networks

Read More...

Page 562«..1020..561562563564..570580..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick